The non-Hodgkin lymphoma survival rate is steadily improving as researchers continue to discover new and better ways to diagnose and treat the condition in its earliest stages. Even so, it is important to keep in mind that survival rates are usually calculated based on the previous outcomes of large numbers of people who had a certain condition. As such, they cannot predict what will happen in a specific person’s case with any degree of certainty.
Scientists have identified a number of individual factors that, while unaccounted for in the general non-Hodgkin lymphoma survival rate, can influence a patient’s prognosis. These include:
- The stage of the lymphoma at the time of diagnosis
- The specific subtype of non-Hodgkin lymphoma
- The type of treatment provided and the cancer’s response
- Whether the cancer has spread to tissues or organs beyond the lymphatic system
- The level of lactate dehydrogenase (LDH) in a patient’s blood
- A patient’s ability to function and perform daily activities
- A patient’s age and overall health
At Moffitt Cancer Center, our patients benefit not only from comprehensive treatments provided by a multispecialty team of experts, but also from one of the most active research programs in the nation. Our breakthroughs in cancer prevention, diagnosis and treatment have earned us worldwide recognition as a Comprehensive Cancer Center, a prestigious designation awarded by the National Cancer Institute. Through our robust clinical trials program, we offer our patients frequent opportunities to participate in promising research studies for every type and stage of non-Hodgkin lymphoma.
Referrals are not required to consult with the cancer experts at Moffitt. To schedule an appointment, call 1-888-663-3488 or submit a new patient registration form online. Our team can provide you with more detailed information regarding the non-Hodgkin lymphoma survival rate, as well as individualized advice on how you can improve your own prognosis and quality of life.